ABVX: Abivax Pharma Price to Sales
ABIVAX is an ambitious biotech developer gaining recognition through successful tests of anti-inflammatory agents. However, a lack of sales and limited capital leave the company vulnerable to the outcome of final trials. Growth is accelerating through partnerships with clinics and research centers. The company's normalized P/S helps assess the balance between demand and revenue, where the level captures the current state of the asset.
Abivax Pharma (ABVX) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
ABVX - Net Profit|Expected Profit ABIVAX|ABVX - Price to Earnings Ratio|Future Price to Earnings Abivax|ABVX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Abivax Pharma|ABVX - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Abivax|ABVX - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months abivax.com|ABVX - Earnings growth in current year|Earnings growth forecast for next year ABIVAX
- issuer revenue and sales details:
General company analysis:ABVX abivax.com
The P/S multiple is calculated as the ratio of market capitalization to annual revenue, determining the cost of each ruble of sales to assess whether an asset is overvalued. For ABIVAX (ABVX), the market P/S multiple reflects market expectations for the commercial success of obefazimod, where the current business valuation depends directly on clinical trial results and the prospects of partnerships with Big Pharma.
Who ABIVAX competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|ADMA Biologics Inc (ADMA) - Price to Sales|Protagonist Therapeutics Inc - P/S Multiple|IMVT - P/S Multiple|KNSA: P/S Multiple|GRFS (grifols.com) - Price-to-Revenue Ratio|ADPT (Adaptive Biotechnologies Corporation) - P/S Multiple|Celldex Therapeutics Inc (CLDX) - Price-to-Revenue Coefficient|Market Cap to Revenue AUPH (Aurinia Pharma)|Price-to-Revenue Ratio BCRX (BioCryst Corp)|P/S Multiple VERA (Vera Therapeutics, Inc.)|P/S Multiple dianthustx.com DNTH|PHVS: Market Cap to Revenue|ABCL (AbCellera Biologics Inc.) - Market Cap to Revenue Ratio|TRML: P/S Multiple|Precigen Corp (PGEN) - P/S Multiple|PHAR (Pharming Group N.V.) - P/S Multiple|Price-to-Revenue Ratio NKTR|Market Cap to Revenue UPB (Upstream Bio)|Price-to-Revenue Ratio ZBIO (Zenas Bio)|Immunome Corp - Market Cap to Revenue|GOSS: Market Cap to Revenue Ratio|KALV - Price-to-Revenue Ratio|Price-to-Sales Ratio SEPN|PVLA: P/S Multiple|Savara Inc - Market Capitalization-to-Revenue Ratio|RIGL (Rigel Pharmaceuticals Inc) - P/S Multiple|P/S Multiple AnaptysBio Inc.|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|ENGN (engene.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio RAPT Therapeutics RAPT|JBIO - Market Cap to Revenue|Aclaris - P/S Multiple|KYTX - P/S Multiple|TLSA (Tiziana Life Sciences) - Market Cap to Revenue|cabalettabio.com - Market Capitalization-to-Revenue Ratio|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|Theratechnologies, Inc. (THTX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|Market Cap to Revenue Eledon Pharmaceuticals, Inc ELDN|Price-to-Revenue Ratio Agenus AGEN|CLYM - Market Cap to Revenue|ZURA: Market Cap to Revenue|ATYR - P/S Multiple|adagene.com (ADAG) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio IMA|STTK (Shattuck Labs Inc) - P/S Multiple|Price to Sales Equillium Bio EQ|P/S Multiple CNTB|P/S Multiple immunic-therapeutics.com (IMUX)|P/S Multiple ATRA (Atara Bio)|InflaRx NV - Price-to-Revenue Ratio|X4 Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient Adicet Bio ACET|CELU (celularity.com) - Market Cap to Revenue|INMB (INmune Bio Inc) - Price-to-Revenue Ratio|BRNS (Barinthus Bio) - P/S Multiple|P/S Multiple Kezar Life Sciences Inc|Market Cap to Revenue SABS (SAB Biotherapeutics)|akaritx.com - Market Cap to Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|P/S Multiple Q32 Bio Inc QTTB|GeoVax Labs Inc - P/S Multiple|EDSA: Price-to-Revenue Ratio|IBIO (iBio, Inc.) - Market Cap to Revenue|CARM (Carisma Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue XTLB|Market Cap to Revenue Ratio BOLT (Bolt Bio)|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|APVO: Price-to-Sales Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio - P/S Multiple|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue scinai.com (SCNI)|P/S Multiple CALI|P/S Multiple affimed.com (AFMD)|Allakos - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|Price-to-Revenue Coefficient iteostherapeutics.com ITOS|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Market Cap to Revenue TC BioPharm (Holdings) Plc|Price-to-Revenue Ratio Third Harmonic Bio, Inc
